Wall Street Experts
ver. ZuMIgo(08/25)
Bolt Biotherapeutics, Inc.
Rachunek Zysków i Strat
Przychody TTM (mln): 10
EBIT TTM (mln): -72
| index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
| Rok finansowy |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Przychód (mln) |
0 |
0 |
0 |
1 |
6 |
8 |
8 |
| Przychód Δ r/r |
0.0% |
inf% |
7.4% |
445.5% |
354.7% |
37.5% |
-2.4% |
| Marża brutto |
0.0% |
-11994.0% |
-17370.6% |
-191.4% |
14.6% |
76.1% |
100.0% |
| EBIT (mln) |
-12 |
-31 |
-49 |
-93 |
-90 |
-76 |
-73 |
| EBIT Δ r/r |
0.0% |
166.3% |
58.8% |
88.7% |
-2.7% |
-15.6% |
-4.1% |
| EBIT (%) |
0.0% |
-14404.2% |
-21290.9% |
-7364.1% |
-1576.6% |
-967.4% |
-949.9% |
| Koszty finansowe (mln) |
0 |
0 |
0 |
0 |
-2 |
0 |
0 |
| EBITDA (mln) |
-11 |
-31 |
-37 |
-86 |
-89 |
-74 |
-66 |
| EBITDA(%) |
0.0% |
-14228.8% |
-15942.0% |
-6786.6% |
-1547.5% |
-943.5% |
-864.2% |
| Podatek (mln) |
0 |
-0 |
12 |
6 |
-2 |
0 |
0 |
| Zysk Netto (mln) |
-12 |
-30 |
-72 |
-104 |
-86 |
-69 |
-63 |
| Zysk netto Δ r/r |
0.0% |
158.9% |
140.9% |
44.4% |
-17.7% |
-19.4% |
-8.8% |
| Zysk netto (%) |
0.0% |
-13955.8% |
-31287.4% |
-8285.2% |
-1499.0% |
-878.6% |
-820.8% |
| EPS |
-1.23 |
-0.85 |
-1.99 |
-2.79 |
-2.3 |
-1.83 |
-1.65 |
| EPS (rozwodnione) |
-1.23 |
-0.85 |
-1.99 |
-2.79 |
-2.3 |
-1.83 |
-1.65 |
| Ilośc akcji (mln) |
9 |
35 |
36 |
37 |
37 |
38 |
38 |
| Ważona ilośc akcji (mln) |
9 |
35 |
36 |
37 |
37 |
38 |
38 |
| Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |